Genvor Announces Issuance of New U.S. Patent for Corn with Antifungal Peptide
Genvor (OTCQB: GNVR) announced the USPTO issued U.S. Patent No. 12,458,684 on Nov 12, 2025 for “Transgenic Corn with Antifungal Peptide AGM182,” co‑assigned to Genvor and the USDA. The patent covers transgenic corn expressing AGM182 designed to reduce fungal infections and mycotoxin accumulation, including activity shown against Aspergillus flavus and Fusarium species.
Published results cited in Plant Science and Plant Disease report 76–98% reduction in total aflatoxin contamination, no adverse plant growth or yield effects, and no observed mammalian toxicity. The company highlights potential foliar spray and transgenic seed applications to address multi‑billion dollar U.S. corn losses from fungal diseases.
Genvor (OTCQB: GNVR) ha annunciato che l'USPTO ha rilasciato la Patente U.S. n. 12,458,684 il 12 novembre 2025 per “Mais transgenico con peptide antifungino AGM182”, co-assegnata a Genvor e al USDA. La patente copre mais transgenico che esprime AGM182 progettato per ridurre infezioni fungine e l'accumulo di micotossine, inclusa l'attività dimostrata contro Aspergillus flavus e le specie di Fusarium. Risultati pubblicati citati su Plant Science e Plant Disease riportano una riduzione del 76–98% della contaminazione totale da aflatossine, nessun effetto avverso sulla crescita o sul rendimento delle piante e nessuna tossicità mammifera osservata. L'azienda evidenzia potenziali applicazioni come spray fogliare e sementi transgenici per affrontare le perdite miliardarie di dollari statunitensi dovute a malattie fungine.
Genvor (OTCQB: GNVR) anunció que la USPTO emitió la Patente de EE. UU. n.º 12,458,684 el 12 de noviembre de 2025 para “Maíz transgénico con el péptido antifúngico AGM182”, coasignada a Genvor y al USDA. La patente cubre maíz transgénico que expresa AGM182 diseñado para reducir infecciones fúngicas y la acumulación de micotoxinas, incluida la actividad demostrada contra Aspergillus flavus y las especies de Fusarium. Resultados publicados citados en Plant Science y Plant Disease reportan una reducción del 76–98% en la contaminación total por aflatoxinas, sin efectos adversos en el crecimiento de las plantas ni en el rendimiento, y sin toxicidad en mamíferos observada. La empresa destaca posibles aplicaciones en forma de rociado foliar y semillas transgénicas para abordar las pérdidas de miles de millones de dólares en EE. UU. por enfermedades fúngicas.
제nvor (OTCQB: GNVR)는 USPTO가 미국 특허 제12,458,684호를 2025년 11월 12일에 발급했다고 발표했습니다. “항진균 펩타이드 AGM182를 가진 트랜스제닉 옥수수”로, 제nvor와 USDA에 공동 할당되었습니다. 이 특허는 AGM182를 발현하도록 설계된 트랜스제닉 옥수수가 진균 감염과 미코톡신 축적을 줄이도록 하는 것을 다루며, Aspergillus flavus 및 Fusarium 종에 대해 활성성을 보인다고 명시합니다.
Plant Science와 Plant Disease에 실린 결과는 총 아플라톡신 오염 감소 76–98%를 보고하고, 식물의 성장이나 수확량에 악영향이 없고, 포유류 독성도 관찰되지 않았다고 밝힙니다. 이 회사는 다년간의 미국 옥수수 손실을 초래하는 진균 병해를 해결하기 위한 잎사귀 스프레이 및 트랜스제닉 씨앗 적용 가능성을 강조합니다.
Genvor (OTCQB: GNVR) a annoncé que l'USPTO a délivré le Brevet américain n° 12,458,684 le 12 novembre 2025 pour « Maïs transgénique avec le peptide antifongique AGM182 », co-affecté à Genvor et à l’USDA. Le brevet couvre un maïs transgénique exprimant AGM182 conçu pour réduire les infections fongiques et l'accumulation de micotoxines, y compris une activité démontrée contre Aspergillus flavus et les espèces de Fusarium. Des résultats publiés cités dans Plant Science et Plant Disease rapportent une réduction de 76 à 98 % de la contamination totale par les aflatoxines, pas d’effets négatifs sur la croissance ou le rendement des plantes et aucune toxicité chez les mammifères observée. L'entreprise souligne des applications potentielles sous forme de pulvérisation foliaire et de semences transgéniques pour faire face aux pertes de milliards de dollars américains dues aux maladies fongiques.
Genvor (OTCQB: GNVR) kündigte an, dass das USPTO US-Patent Nr. 12,458,684 am 12. November 2025 für „Transgener Mais mit dem antifungalen Peptid AGM182“ erteilt wurde, das gemeinsam Genvor und dem USDA zugeordnet ist. Das Patent deckt transgenen Mais ab, der AGM182 exprimiert und darauf ausgelegt ist, Pilzinfektionen und die Ansammlung von Mykotoxinen zu reduzieren, einschließlich der nachgewiesenen Aktivität gegen Aspergillus flavus und Fusarium-Arten.
Veröffentlichte Ergebnisse, zitiert in Plant Science und Plant Disease, berichten von einer 76–98%igen Reduktion der Gesamtaflatoxinbelastung, keine nachteiligen Auswirkungen auf das Pflanzenwachstum oder die Ausbeute und keine beobachtete Toxizität für Säugetiere. Das Unternehmen hebt potenzielle Anwendungen als Blatt-Sprühbehandlung und transgene Samenanwendungen hervor, um die milliardenschweren Verluste der USA durch Pilzkrankheiten anzugehen.
جِنفور (OTCQB: GNVR) أعلن أن مكتب براءات الاختراع الأميركي (USPTO) أصدر البراءة الأمريكية رقم 12,458,684 في 12 نوفمبر 2025 لاسم "الذُرة المعدّلة وراثياً مع الببتيد المضاد للفطريات AGM182"، وهي مُشترك في منحها لجينفور ووزارة الزراعة الأميركية USDA. تغطي البراءة الذُرة المعدّلة وراثياً التي تعبر AGM182 المصممة لتقليل الإصابات الفطرية وتراكم الميكوتوكسينات، بما في ذلك النشاط المبَيَّن ضد Aspergillus flavus وأنواع Fusarium. النتائج المنشورة المشار إليها في Plant Science وPlant Disease تُبلغ عن خفض بنسبة 76–98% في التلوث الكلي بالافلاتوكسين، ولا آثار سلبية على نمو النبات أو محصوله، ولا سمية مُلاحظَة للحيوانات الثديية. وتسلط الشركة الضوء على تطبيقات محتملة لرش أوراق النبات وبذور مُعدَّلة وراثياً لمعالجة الخسائر بسوق الذرة الأميركية التي تَقْدُر بمليارات الدولارات بسبب الأمراض الفطرية.
- U.S. Patent No. 12,458,684 issued on Nov 12, 2025
- Patent co‑assigned to Genvor and USDA
- 76–98% reduction in total aflatoxin contamination reported
- No adverse plant growth or yield effects reported
- No observed mammalian toxicity reported
- None.
Woodland, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, announced today the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,458,684, titled “Transgenic Corn with Antifungal Peptide AGM182.” The patent, co-assigned to Genvor Inc. and the United States Department of Agriculture (USDA), covers transgenic corn expressing the antifungal peptide AGM182, designed to combat fungal infections in maize.
The patent covers novel biological compositions shown to reduce the presence of Aspergillus flavus, a fungal pathogen known to produce aflatoxins, which is a naturally occurring toxic and carcinogenic compound that can contaminate corn and other crops. Research supporting the patent also demonstrated activity against additional mycotoxin-producing fungi, including those associated with Fusarium species.
“This patent represents a significant milestone in Genvor’s growth as we continue to expand our intellectual property portfolio and deliver sustainable solutions for global agriculture,” said Chad Pawlak, Chief Executive Officer of Genvor. “The AGM182 technology exemplifies our BioCypher™ Algorithm’s power to design next-generation antimicrobial peptides that are highly active, versatile, and effective in foliar formulations as well as in transgenic seed applications.”
Economic losses from fungal diseases in corn are substantial, with total annual U.S. losses estimated between
Genvor’s newly issued patent directly addresses these challenges through novel biological compositions and methods designed to reduce fungal infection and mycotoxin production. Early research demonstrates activity against Aspergillus flavus and Fusarium species, which are key contributors to yield loss and grain contamination. These discoveries form the foundation for potential foliar spray and seed trait solutions that could help protect crops both above and below ground.
Published research in Plant Science and Plant disease validates the technology’s effectiveness in transgenic corn seeds, demonstrating:
- 76–
98% reduction in total aflatoxin contamination - No adverse effects on plant growth or yield
- Proven safety, with no observed mammalian toxicity
Dr. Jesse Jaynes, Professor of Biological Sciences at Tuskegee University and founding scientist behind Genvor’s core technologies, contributed to the development of AGM182. “This innovation represents decades of foundational research translated into a practical, scalable agricultural solution,” said Dr. Jaynes. “It reflects how Genvor’s BioCypher platform can unlock nature’s molecular diversity to deliver safe, sustainable, and highly effective peptide technologies for global agriculture.”
About Genvor
Genvor (OTCQB: GNVR) is pioneering the future of sustainable agriculture through its proprietary AI-accelerated peptide design platform that transforms single discoveries into multi-crop protection and optimization opportunities across diverse agricultural environments. The company’s proprietary BioCypher Algorithm combines computational biology, machine learning, and regulatory benchmarks to create peptides that optimize agricultural outcomes with biological safety. With multiple patents and proprietary peptides in active development, Genvor offers ready-to-deploy licensing opportunities that integrate with existing production infrastructure and regulatory frameworks. For more information, visit www.genvor.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied. Genvor undertakes no obligation to update forward-looking statements except as required by applicable law.
Contacts:
Investor Relations
Genvor Incorporated
Marketing@genvor.com
www.genvor.com
Media
Carly Scaduto
carly@carlyscadutoconsulting.com
FAQ
What did Genvor (GNVR) announce on November 12, 2025?
How effective is AGM182 against aflatoxin in Genvor (GNVR) research?
Does the Genvor (GNVR) patent cover applications beyond seed traits?
Is the Genvor (GNVR) patent jointly owned with a government agency?
Were any safety concerns reported for AGM182 in Genvor (GNVR) research?
